Abstract: Allo-HSCT is a potentially curative treatment for hematologic diseases, but long-term quality of life (QoL) remains a concern. Factors like GVHD, comorbidities, and post-transplant complications can impact survivorship. Understanding QoL in long-term survivors is key to improving care strategies. This observational study included allo-HSCT patients aged 18 years, transplanted between January 2010 and December 2015. QoL was assessed by telephone using FACT-BMT and EQ-5D-5L, along with clinical data. Statistical analyses examined associations between QoL and clinical factors. Sixty-seven long-term survivors participated (median follow-up: 7 years). The mean FACT-BMT score was 115.2/148, indicating generally good QoL. However, patients with active GVHD showed reduced physical and emotional functioning. Stem cell source also influenced specific FACT-BMT subscores. Long-term QoL after allo-HSCT is generally favorable, but physical and emotional challenges persist, especially with active GVHD. Targeted interventions and proactive management are crucial to improving overall survivorship care.

Autoría

Descargar referencia